Published in Haematologica on June 24, 2012
Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol (2013) 1.44
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs (2013) 0.96
Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol (2015) 0.92
Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J Pharmacol (2014) 0.90
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol (2012) 0.84
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica (2015) 0.82
Comparative drug screening in NUT midline carcinoma. Br J Cancer (2014) 0.82
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One (2013) 0.80
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. J Med Chem (2016) 0.79
Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. Assay Drug Dev Technol (2015) 0.78
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC Pharmacol Toxicol (2013) 0.78
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res (2014) 0.78
Overview of CDK9 as a target in cancer research. Cell Cycle (2016) 0.78
Recent Advances on Small-Molecule Survivin Inhibitors. Curr Med Chem (2015) 0.76
Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. PLoS One (2017) 0.75
Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. Clin Cancer Res (2017) 0.75
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67
Age and acute myeloid leukemia. Blood (2006) 6.46
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem (2001) 5.36
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol (2006) 4.20
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol (2001) 3.55
Randomized phase II clinical trials. Cancer Treat Rep (1985) 3.19
Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst (2000) 2.62
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol (2007) 2.30
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res (1996) 2.24
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res (2005) 2.19
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res (2002) 1.99
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res (2009) 1.92
Proper inference from Simon's two-stage designs. Stat Med (2008) 1.75
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
New designs for phase 2 clinical trials. Blood (2003) 1.53
Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res (1996) 1.50
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res (2005) 1.44
Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res (1999) 1.40
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood (2011) 1.36
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res (1997) 1.33
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res (2007) 1.23
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res (2005) 1.23
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica (2010) 1.17
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res (2003) 1.17
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res (2003) 1.13
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther (2006) 1.09
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ (2001) 1.07
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother (2003) 1.07
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med (2004) 5.47
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Comparison of "B" readers' interpretations of chest radiographs for asbestos related changes. Acad Radiol (2004) 4.71
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood (2009) 4.64
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
The accuracy of surrogate decision makers: a systematic review. Arch Intern Med (2006) 4.17
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature (2012) 4.01
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 3.73
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Development in infants with autism spectrum disorders: a prospective study. J Child Psychol Psychiatry (2006) 3.54
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res (2008) 3.51
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood (2009) 3.40
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Social and communication development in toddlers with early and later diagnosis of autism spectrum disorders. Arch Gen Psychiatry (2007) 3.29
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood (2008) 3.05
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood (2002) 3.03
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med (2015) 3.00
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol (2011) 2.89
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol (2007) 2.69
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 2.66
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol (2011) 2.59
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood (2011) 2.52
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol (2003) 2.41
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood (2009) 2.25
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw (2009) 2.25
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood (2013) 2.23
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood (2006) 2.18
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood (2011) 2.14
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2005) 2.10
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood (2004) 2.03
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol (2009) 2.03
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood (2010) 2.01
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 1.99
Acute myeloid leukemia. J Natl Compr Canc Netw (2012) 1.96
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res (2009) 1.92
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis (2007) 1.91
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol (2013) 1.88
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer (2006) 1.88
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One (2007) 1.87
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys (2007) 1.86
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res (2009) 1.85
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol (2008) 1.84
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn (2003) 1.82